×
Evotec AG Net Current Debt 2010-2025 | EVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Evotec AG net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Evotec AG Net Current Debt 2010-2025 | EVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Evotec AG net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.3B
Zoetis (ZTS)
$66.2B
Takeda Pharmaceutical (TAK)
$45.9B
Daiichi Sankyo, - (DSNKY)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$25B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.2B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.5B
Stevanato Group S.p.A (STVN)
$7.5B
Corcept Therapeutics (CORT)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B